First Bank & Trust Buys 2,801 Shares of Sanofi (NASDAQ:SNY)

First Bank & Trust raised its stake in Sanofi (NASDAQ:SNY) by 5.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 59,267 shares of the company’s stock after acquiring an additional 2,801 shares during the period. First Bank & Trust’s holdings in Sanofi were worth $3,416,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Register Financial Advisors LLC bought a new stake in shares of Sanofi in the 1st quarter worth about $29,000. BKM Wealth Management LLC increased its holdings in shares of Sanofi by 74.3% during the first quarter. BKM Wealth Management LLC now owns 8,314 shares of the company’s stock worth $404,000 after buying an additional 3,543 shares in the last quarter. Park Place Capital Corp raised its stake in shares of Sanofi by 6.3% in the first quarter. Park Place Capital Corp now owns 9,068 shares of the company’s stock valued at $441,000 after acquiring an additional 534 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Sanofi by 773.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,651 shares of the company’s stock worth $275,000 after acquiring an additional 5,004 shares in the last quarter. Finally, Sivia Capital Partners LLC boosted its holdings in shares of Sanofi by 17.9% in the 1st quarter. Sivia Capital Partners LLC now owns 7,199 shares of the company’s stock worth $350,000 after acquiring an additional 1,091 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Trading Up 4.4 %

Shares of SNY traded up $2.29 during trading hours on Friday, hitting $54.34. 3,251,878 shares of the stock traded hands, compared to its average volume of 2,033,069. The business has a fifty day moving average of $56.08 and a 200-day moving average of $51.72. The firm has a market capitalization of $137.63 billion, a PE ratio of 27.31, a price-to-earnings-growth ratio of 1.40 and a beta of 0.60. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.95 EPS. Analysts expect that Sanofi will post 4.23 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SNY. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, Argus upped their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.